Loading patent…
AssigneeIsis Innovation Limited
InventorsRobert Paul Anderson, Adrian Vivian Hill, Derek Parry Jewell
Estimating the term…
A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence 62PQPELPY68 (SEQ ID NO:1), and fusion proteins, pharmaceutical compositions, and kits comprising the same, are provided herewith. Also provided are methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising contacting a sample from the individual with a peptide analogue and determining in vitro whether T cells in the sample recognize the peptide analogue.
-59. (canceled)
A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognised by a T cell receptor or an antibody that recognises an epitope comprising sequence 62PQPELPY68 or 57QLQPFPQPELPYPQPQS73.
A method for identifying an analogue of a peptide comprising the amino acid sequence 62pQPELPY68 or 57QLQPFPQPELPYPQPQS73 comprising:
A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognised by a T cell receptor or an antibody that recognises an epitope comprising sequence 63QPELP67.
A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognised by a T cell receptor or an antibody that recognises an epitope comprising sequence 64PELPY68.
Dependencies are inferred from the claim text.